Patrick Smeele

Research output

Research output per year 2021 2021 2022 2023 2023

• 8 Article
• 4 Meeting Abstract
• 3 Comment/Letter to the editor

Research output per year

Research output per year

Search results

• 2023

  Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients

  Asmus, E., Karle, W., Brack, M. C., Wittig, C., Behrens, F., Reinshagen, L., Pfeiffer, M., Schulz, S., Mandzimba-Maloko, B., Erfinanda, L., Perret, P. L., Michalick, L., Smeele, P. J., Lim, E. H. T., van den Brom, C. E., Vonk, A. B. A., Kaiser, T., Suttorp, N., Hippenstiel, S., Sander, L. E., & 10 othersKurth, F., Rauch, U., Landmesser, U., Haghikia, A., Preissner, R., Bogaard, H. J., Witzenrath, M., Kuebler, W. M., Szulcek, R. & Simmons, S., 1 Mar 2023, In: European respiratory journal. 61, 3, 2202009.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

• Differences in incidence, nature of symptoms, and duration of long COVID among hospitalised migrant and non-migrant patients in the Netherlands: a retrospective cohort study

  Chilunga, F. P., Appelman, B., van Vugt, M., Kalverda, K., Smeele, P., van Es, J., Wiersinga, W. J., Rostila, M., Prins, M., Stronks, K., Norredam, M. & Agyemang, C., Jun 2023, In: The Lancet Regional Health - Europe. 29, 100630.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  10 Citations (Scopus)

• Endothelial Permeability and the Angiopoietin/Tie2 System Following Mild and Severe COVID-19

  Ibelings, R., van den Brom, C. E. & the Amsterdam UMC COVID-19 biobank study group, 1 Sept 2023, In: Artery Research. 29, 3, p. 83-93 11 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

• Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

  COVID-STORM Clinicians, Amsterdam UMC Covid-19 Biobank, COVID Human Genetic Effort, COVIDeF Study Group, French COVID Cohort Study Group, CoV-Contact Cohort, COVID Clinicians, NIAID-USUHS COVID Study Group, Orchestra Working Group, Botta, M., de Bruin, S., Bulle, E., Dijkstra, M., Dongelmans, D. A., Dujardin, R. W. G., Goorhuis, B., Hafkamp, F., Hagens, L., Hamann, J., Paulus, F., & 11 othersPina-Fuentes, D. A. I., Raasveld, J., de Rotte, M. C. F. J., Schultz, M. J., Schrauwen, F. A. P., Slim, M. A., Smit, M., Stijnis, C. S., Stilma, W., Zwinderman, A. H. & Vlaar, A. P. J., 1 Dec 2023, In: Genome Medicine. 15, 1, p. 22 22.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  17 Citations (Scopus)
• 2022

  90-Day Clinical Outcome of Hospitalized Covid-19 Patients Treated with Imatinib

  Schippers, J., Duijvelaar, E., Smeele, P., De Raaf, M., Blok, S., Vanhove, A., De Man, F., Bogaard, H. J. & Aman, J., 1 May 2022, In: American journal of respiratory and critical care medicine. 205

  Research output: Contribution to journal › Meeting Abstract › Academic

• Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the phase 2 PANAMO trial

  the Amsterdam UMC COVID-19 Biobank Investigators, 1 Dec 2022, In: Respiratory research. 23, 1, 6 p., 375.

  Research output: Contribution to journal › Comment/Letter to the editor › Academic

  Open Access
  7 Citations (Scopus)

• Cardiac Safety of Imatinib for the Treatment of COVID-19: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial

  CounterCOVID Collaborative Group, 28 Dec 2022, In: Journal of Cardiovascular Pharmacology. 80, 6, p. 783-791 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review
  4 Citations (Scopus)

• Cardiac Safety of Imatinib for the Treatment of Covid-19: Results from a Randomized, Double Blind, Placebo-Controlled Trial

  Duijvelaar, E., Vanhove, A., Schippers, J. R., Smeele, P. J., de Man, F. S., Pinto, Y. M. & Bogaard, H. J., 1 May 2022, In: American journal of respiratory and critical care medicine. 205

  Research output: Contribution to journal › Meeting Abstract › Academic

• Immunomodulation and endothelial barrier protection mediate the association between oral imatinib and mortality in hospitalised COVID-19 patients

  CounterCOVID study group, 1 Dec 2022, In: The European respiratory journal. 60, 6, 2200780.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  15 Citations (Scopus)

• Long-term clinical outcomes of COVID-19 patients treated with imatinib

  CounterCOVID Collaborative Group, 1 Apr 2022, In: The Lancet Respiratory Medicine. 10, 4, p. e34-e35

  Research output: Contribution to journal › Comment/Letter to the editor › Academic

  Open Access
  19 Citations (Scopus)

• Oral Imatinib Reduces Mortality in Hospitalized COVID-19 Patients Through Endothelial Barrier Protection and Immunomodulation

  De Brabander, J., Duijvelaar, E., Schippers, J. R., Smeele, P. J., Duitman, J., Aman, J., Bogaard, H. J., van der Poll, T. & Bos, L. D. J., 1 May 2022, In: American journal of respiratory and critical care medicine. 205

  Research output: Contribution to journal › Meeting Abstract › Academic
• 2021

  Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

  COVID Human Genetic Effort, Imagine COVID-Group, Danish CHGE, CONSTANCES cohort, Etablissement du Sang study group, St James's Hospital, SARS CoV2 Interest group, 3C-Dijon Study, COVID Clinicians, CoV-Contact Cohort, NIAID Immune Response to COVID Group, Cerba HealthCare, French COVID Cohort Study Group, HGID Lab, COVID-STORM Clinicians, NH-COVAIR Study Group, The Danish Blood Donor Study (DBDS), The Milieu Intérieur Consortium & Amsterdam UMC Covid-19 Biobank, 19 Aug 2021, In: Science immunology. 6, 62, 26 p., eabl4340.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  327 Citations (Scopus)

• Correction to Lancet Respir Med 2021; published online June 17, https://doi.org/10.1016/S2213-2600(21)00237-X (The Lancet Respiratory Medicine, (S221326002100237X), (10.1016/S2213-2600(21)00237-X))

  Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J. R., Smeele, P. J., Azhang, S., Bartelink, I. H., Bayoumy, A. A., Bet, P. M., Boersma, W., Bonta, P. I., Boomars, K. A. T., Bos, L. D. J., van Bragt, J. J. M. H., Braunstahl, G-J., Celant, L. R., Eger, K. A. B., Geelhoed, J. J. M., van Glabbeek, Y. L. E., & 45 othersGrotjohan, H. P., Hagens, L. A., Happe, C. M., Hazes, B. D., Heunks, L. M. A., van den Heuvel, M., Hoefsloot, W., Hoek, R. J. A., Hoekstra, R., Hofstee, H. M. A., Juffermans, N. P., Kemper, E. M., Kos, R., Kunst, P. W. A., Lammers, A., van der Lee, I., van der Lee, E. L., Maitland-van der Zee, A-H., Asam, P. F. M. M., Mieras, A., Muller, M., Neefjes, E. C. W., Nossent, E. J., Oswald, L. M. A., Overbeek, M. J., Pamplona, C. C., Paternotte, N., Pronk, N., de Raaf, M. A., van Raaij, B. F. M., Reijrink, M., Schultz, M. J., Neto, A. S., Slob, E. M. A., Smeenk, F. W. J. M., Smit, M. R., Smits, A. J., Stalenhoef, J. E., Tuinman, P. R., Vanhov, A. L. E. M., Wessels, J. N., van Wezenbeek, J. C. C., Noordegraaf, A. V., de Ma, F. S. & Bogaard, H. J., Aug 2021, In: Lancet respiratory medicine. 9, 8, p. e84

  Research output: Contribution to journal › Comment/Letter to the editor › Academic

  Open Access

• Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial

  Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J. R., Smeele, P. J., Azhang, S., Bartelink, I. H., Bayoumy, A. A., Bet, P. M., Boersma, W., Bonta, P. I., Boomars, K. A. T., Bos, L. D. J., van Bragt, J. J. M. H., Braunstahl, G-J., Celant, L. R., Eger, K. A. B., Geelhoed, J. J. M., van Glabbeek, Y. L. E., & 45 othersGrotjohan, H. P., Hagens, L. A., Happe, C. M., Hazes, B. D., Heunks, L. M. A., van den Heuvel, M., Hoefsloot, W., Hoek, R. J. A., Hoekstra, R., Hofstee, H. M. A., Juffermans, N. P., Kemper, E. M., Kos, R., Kunst, P. W. A., Lammers, A., van der Lee, I., van der Lee, E. L., Maitland-van der Zee, A-H., Mau Asam, P. F. M., Mieras, A., Muller, M., Neefjes, L., Nossent, E. J., Oswald, L. M. A., Overbeek, M. J., Pamplona, C., Paternotte, N., Pronk, N., de Raaf, M. A., van Raaij, B. F. M., Reijrink, M., Schultz, M. J., Serpa Neto, A., Slob, E. M., Smeenk, F. W. J. M., Smit, M. R., Smits, A. J., Stalenhoef, J. E., Tuinman, P. R., Vanhove, A. L. E. M., Wessels, J. N., van Wezenbeek, J. C. C., Vonk Noordegraaf, A., de Man, F. S. & Bogaard, H. J., Sept 2021, In: lancet. Respiratory medicine. 9, 9, p. 957-968 12 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  76 Citations (Scopus)

• Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19

  Aman, J., Duijvelaar, E., Botros, L., Kianzad, A., Schippers, J., Smeele, P., Azhang, S., Bartelink, I., Bet, P., Boersma, W., Boomars, K., Bonta, P., Bos, L., Van Bragt, J., Braunstahl, G-J., Celant, L., Eger, K., Geelhoed, M., Van Glabbeek, Y., Grotjohan, H., & 39 othersHagens, L., Happe, C., Heunks, L., Van Den Heuvel, M., Hoefsloot, W., Hoek, R., Hoekstra, R., Hofstee, H., Vanhove, A., Juffermans, N., Lammers, M., Kos, R., Kemper, M., Kunst, P., Van Der Lee, I., Van Der Lee, L., Mau-Asam, P., Maitland-Van Der Zee, A-H., Mieras, A., Nossent, E., Overbeek, M., Oswald, L., Paternotte, N., Pamplona, C., Pronk, N., De Raaf, M., Slob, E., Neto, A. S., Schultz, M., Smit, M., Smeenk, F., Smits, J., Stalenhoef, J., Tuinman, P. R., Wessels, J., Van Wezenbeek, J., Noordegraaf, A. V., Handoko-De Man, F. & Bogaard, H. J., 5 Sept 2021, In: European respiratory journal. 58

  Research output: Contribution to journal › Meeting Abstract › Academic